SEC Form 4 · accession 0001193125-26-276149
4D Molecular Therapeutics, Inc. · FDMT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John F Milligan
Director
Period of report
Jun 17, 2026
Accepted (ET)
Jun 18, 2026 · 5:32 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001650648
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $9.42 | Jun 17, 2026 | A | 75,000 | A | — | Jun 16, 2036 | Common Stock | 75,000 | 75,000 | D |
Explanation of responses
- F1Automatically granted pursuant to the terms of the Company's non-employee director compensation program.
- F2The stock option vests and becomes exercisable with respect to 1/3 of the total shares on June 17, 2027 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on June 17, 2029. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan).